News

23 Apr 2018

Medgaget Interview: 4Dx Uses Algorithms to Better Visualize Lung Function

Chronic obstructive pulmonary disease affects millions of people in the United States. The main method of diagnosis is the pulmonary function tests (PFTs), in which a patient breathes into a machine that measures pulmonary parameters. The disadvantage, however, is that pulmonary function tests take an “average” of a patient’s lung without being able to detect […]

READ POST
23 Mar 2018

Series B capital round update

Melbourne, Australia, March 2018: 4Dx Limited is pleased to announce that the $5M Series B capital round is fully subscribed. However, based on continued strong interest in the round, the Board has agreed to extend the offer period for a limited time to accept oversubscriptions. 4Dx Chairman & CEO, Andreas Fouras, said, “4Dx is extremely […]

READ POST
19 Mar 2018

4Dx FDA Regulatory Update

4Dx attended a 510(k) pre-submission meeting with the FDA in Silver Spring, Maryland, on March 15th, well ahead of the planned date of April 26th.  The meeting was very cordial and productive, providing 4Dx with valuable feedback regarding our planned pipeline of regulatory clearances.  Approved FDA meeting minutes typically take up to a month to […]

READ POST
08 Jan 2018

4Dx Lung Technology’s Equine Application Featured

From The Sydney Morning Herald DECEMBER 31 2017: 4Dx’s dimensional imaging technology largely focuses on early detection and monitoring of lung diseases in humans, such as cystic fibrosis. Now, 4Dx is keen to adapt the technology to racehorses and has engaged leading Australian equine veterinary surgeon Glenn Robertson-Smith to explore its application. 4Dx and Dr Robertson-Smith have […]

READ POST
31 Oct 2017

4Dx participates in Great Strides run for cystic Fibrosis

Last Sunday, the 4Dx team participated in the Melbourne Great Strides 8K to raise money and awareness for Cystic Fibrosis Community Care (CFCC). CFCC is a non-profit organization working to support those living with and affected by cystic fibrosis. 4Dx’s technology aims to help with early detection and monitoring of lung diseases, such as cystic […]

READ POST
08 Sep 2017

4Dx assigned Intellectual Property relating to core 4Dx technology

4Dx is pleased to announce that key intellectual property relating to the Company’s 4DxV technology has been assigned from Monash University to 4Dx Limited. The intellectual property (IP) was developed by 4Dx Chairman and CEO, Andreas Fouras, while working at Monash University and was previously licenced by 4Dx from Monash University. After reaching an investment […]

READ POST
28 Aug 2017

FDA Update & Future Plans

Earlier this year, 4Dx delivered a 510(k) submission to the FDA for clearance of its 4DxV technology in the radiotherapy setting. Following that submission, the FDA responded with a Request for Additional Information. To clarify the FDA’s request, 4Dx sought and gained a meeting with the FDA. While the FDA identified a potential pathway for […]

READ POST
20 Apr 2017

4Dx Preclinical Scanner Project to Rapidly Manufacture 2 Preclinical Scanner Units for Delivery in Major US Hospitals

Melbourne, Australia, 19 April 2017: 4Dx  Group “4Dx”, Hydrix Pty Ltd “Hydrix”, and Monash University are collaborating “4Dx Pre-Clinical Scanner Project consortium” to rapidly manufacture two pre-clinical scanners for delivery to two major American medical research hospitals by the end of the year. A further three units will be supplied to other world leading hospitals […]

READ POST
17 Mar 2017

4Dx visits London, participates in House of Lords event

4Dx is pleased to inform you that our Chairman and CEO, Andreas Fouras, will be lead speaker at a lunchtime debate at the All Party Parliamentary Engineering Group ‘APPEG’ in the House of Lords, London on Tuesday 21st March.  The debate series represents a plank of the APPEG program to enable contact and involvement between parliamentarians and […]

READ POST
19 Feb 2017

4Dx TO PUBLICLY ANNOUNCE PRELIMINARY CLINICAL TRIAL DATA AT PRESTIGIOUS WORLD LUNG IMAGING EVENT

Melbourne, Australia, 20 February, 2017: Dr. Andreas Fouras, founder and CEO of medical technology company 4Dx Limited, will present preliminary clinical data at the prestigious World Lung Imaging Workshop on the 2nd of March at the University of Pennsylvania. The software technology developed by 4Dx provides richer information, allowing for earlier detection of respiratory related […]

READ POST